Business

Biotech, pharma, and money in science

Biotech

The suburbs are cheaper, but they don’t have what Kendall Square has for biotechs: serendipity

By Scott Kirsner — Boston Globe

Pharma

Insys founder gets 5½ years in jail for his role in fentanyl prescription scheme

By Jonathan Saltzman — Boston Globe

23andMe kits
Business

23andMe laying off 14% of employees amid slump in DNA spit kit sales

By Erin Brodwin

Subsys 1600 mcg video
Business

Former Insys executive who dressed as giant fentanyl bottle gets 26-month sentence

By Jonathan Saltzman — Boston Globe

Sunrise Lee, former Insys executive
Biotech

Two more former Insys executives get prison sentences

By Jonathan Saltzman — Boston Globe

Biotech

How swallowing a star might keep you from missing a dose of medicine

By Jonathan Saltzman — Boston Globe

Alexis Borisy and Melanie Nallicheri
Biotech

‘We have a tragedy of the commons’: How a VC thinks his new company can lower drug prices

By Adam Feuerstein and Matthew Herper

JPM 2020 Lombard St
Adam's Take

All talk, no M&A makes for a down JPM Day

By Adam Feuerstein

Biotech

Agios CEO forecasts ‘line of sight’ to more approved drugs and profits

By Adam Feuerstein

Alexis Borisy portrait
Biotech

A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down

By Matthew Herper

Biotech

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

By Adam Feuerstein

DNA strand repair
Biotech

Blueprint gains approval for its first drug, a treatment for a rare gastrointestinal cancer

By Jonathan Saltzman — Boston Globe

Dr. Patrick Soon-Shiong, Cancer MoonShot 2016
Biotech

At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find

By Rebecca Robbins

2019 to Watch Biotech
Biotech

3 trends in biotech to watch in 2020

By Damian Garde

Cambridge: Sarepta
Biotech

Sarepta sells international rights to Duchenne gene therapy to Roche

By Adam Feuerstein

Adenovirus particles
Biotech

Ring Therapeutics is developing a new way to deliver gene therapy

By Jonathan Saltzman — Boston Globe

Genetic sequencing
Business

The FTC moves to block DNA sequencer Illumina’s acquisition of PacBio, calling company a ‘monopolist’

By Matthew Herper

Genome
Biotech

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

By Jonathan Saltzman — Boston Globe

Purdue in the weeds
Business

Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying

By Nicholas Florko

Ubiome Kit
Biotech

Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation

By Erin Brodwin

Kendall - Longfellow bridge
Biotech

In tight Massachusetts job market, it’s relo for biotech and remote for tech hires

By Scott Kirsner — Boston Globe

Bristol-Myers Squibb
Biotech

Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’

By Adam Feuerstein

Biotech

Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version

By Adam Feuerstein

Biotech

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

By Adam Feuerstein and Damian Garde

flat screen TV turning off
Business

How difficult is a $1 billion health-tech fraud? A new indictment makes it sound easy

By Matthew Herper

ASH19 Gene Therapy Sickle Cell
Biotech

Global Blood secures FDA approval for new pill to treat sickle cell disease

By Adam Feuerstein

Human T cells showing nuclei
Business

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

By Sharon Begley

Biotech

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

By Matthew Herper

Money and medicine
Business

Patient charity settles allegations it helped MS drug makers pay kickbacks

By Elizabeth Cooney

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy